.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
Cerilliant
QuintilesIMS
McKinsey
Express Scripts
Argus Health
Medtronic
Johnson and Johnson
Healthtrust

Generated: December 13, 2017

DrugPatentWatch Database Preview

QUILLICHEW ER Drug Profile

« Back to Dashboard

When do Quillichew Er patents expire, and when can generic versions of Quillichew Er launch?

Quillichew Er is a drug marketed by Pfizer Inc and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-one patent family members in fourteen countries.

The generic ingredient in QUILLICHEW ER is methylphenidate hydrochloride. There are thirty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-001Dec 4, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-003Dec 4, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-002Dec 4, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-001Dec 4, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-002Dec 4, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-002Dec 4, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-003Dec 4, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-003Dec 4, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-001Dec 4, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Pfizer IncQUILLICHEW ERmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE, CHEWABLE;ORAL207960-001Dec 4, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: QUILLICHEW ER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,083Orally effective methylphenidate extended release powder and aqueous suspension product► Subscribe
8,883,217Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,778,390Orally effective methylphenidate extended release powder and aqueous suspension product► Subscribe
9,675,704Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,062,667Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,198,864Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,180,100Methylphenidate extended release chewable tablet► Subscribe
8,465,765Orally effective methylphenidate extended release powder and aqueous suspension product► Subscribe
9,522,191Modified release formulations containing drug--ion exchange resin complexes► Subscribe
8,790,700Modified release formulations containing drug-ion exchange resin complexes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: QUILLICHEW ER

Country Document Number Estimated Expiration
Israel194042► Subscribe
World Intellectual Property Organization (WIPO)2007109104► Subscribe
China101400343► Subscribe
European Patent Office2675438► Subscribe
Canada2645855► Subscribe
European Patent Office2884961► Subscribe
Denmark2428205► Subscribe
European Patent Office2018160► Subscribe
European Patent Office2428205► Subscribe
Japan2009530298► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
UBS
Baxter
Julphar
Daiichi Sankyo
Chinese Patent Office
Deloitte
Healthtrust
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot